《大行報告》美銀證券升藥明生物(02269.HK)評級至「買入」 目標價上調至114.6元
美銀證券發表研報指,藥明生物(02269.HK)去年12月宣布旗下上海及無錫工廠都已獲美國商務部從未經核實名單(UVL)中移除,預期在中國防疫限制放寬、重新開放下,有關當局對廠房進行最終用途檢查將更方便。
美銀表示,在客戶端方面,藥明生物的對外合作並未受到UVL影響,去年共新增綜合項目136個,月初又公布與葛蘭素史克(GSK.US)簽署許可協議,相信藥明生物的地緣政治風險正在緩解,業務並未受到影響。
該行又指,藥明生物目前正在擴大全球製造基地,以規避未來潛在的地緣政治風險。管理層曾透露今年非新冠業務收入或按年增長60%,該行將其今明兩年收入預測上調0.4%及0.1%,經調整每股盈利預測上調0.4%及0.1%,並將目標價由91.8元提升至114.6元,評級亦由「中性」升至「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.